Table 1.
Clinicopathologic variables associated with RECIST 1.1
| Characteristics | Effective | Ineffective | P value | |
|---|---|---|---|---|
| N = 30 | N = 26 | |||
| Age | < 65 | 17 (48.6%) | 18 (51.4%) | 0.33 |
| > = 65 | 13 (61.9%) | 8 (38.1%) | ||
| Gender | Male | 17 (56.7%) | 13 (43.3%) | 0.62 |
| Female | 13 (50.0%) | 13 (50.0%) | ||
| BMI | < 18.5 | 1 (20.0%) | 4 (80.0%) | 0.08 |
| 8.5–23.9 | 20 (66.7%) | 10 (33.3%) | ||
| > 23.9 | 9 (42.9%) | 12 (57.1%) | ||
| Position | Gastric | 20 (48.8%) | 21 (51.2%) | 0.24 |
| Esophageal–gastric junction | 10 (66.7%) | 5 (33.3%) | ||
| Lauren | Diffuse | 9 (40.9%) | 13 (59.1%) | 0.37 |
| Non-diffuse | 15 (53.6%) | 13 (46.4%) | ||
| NA | 6 (100.0%) | 0 (0%) | ||
| Liver metastasis | Yes | 2 (40.0%) | 3 (60.0%) | 0.87 |
| No | 28 (54.9%) | 23 (45.1%) | ||
| Lymph node metastasis | Yes | 7 (58.3%) | 5 (41.7%) | 0.76 |
| No | 23 (52.3%) | 21 (47.7%) | ||
| Peritoneal metastasis | Yes | 5 (29.4%) | 12 (70.6%) | 0.02 |
| No | 25 (64.1%) | 14 (35.9%) | ||
| MMR | pMMR | 24 (54.5%) | 20 (45.5%) | 0.47 |
| dMMR | 0 (0%) | 1 (100.0%) | ||
| NA | 6 (54.5%) | 5 (45.5%) | ||
| Differentiation | Medium-low differentiation | 19 (45.2%) | 23 (54.8%) | 0.16 |
| Medium-high differentiation | 7 (77.8%) | 2 (22.2%) | ||
| NA | 4 (80.0%) | 1 (20.0%) | ||
| HER-2 | Positive | 3 (75.0%) | 1 (25.0%) | 0.66 |
| Negative | 23 (50.0%) | 23 (50.0%) | ||
| NA | 4 (66.7%) | 2 (33.3%) | ||
| Clinical N stage | N1 | 3 (42.9%) | 4 (57.1%) | 0.86 |
|
N2 N3 NA |
13 (54.2%) 11 (45.8%) 3 (75.0%) |
11 (45.8%) 9 (54.2%) 2 (25.0%) |
||
| Preoperative staging | IIb | 1 (50.0%) | 1 (50.0%) | 0.44 |
| IIIa | 4 (50.0%) | 4 (50.0%) | ||
| IIIb | 6 (42.9%) | 8 (57.1%) | ||
| IIIc | 6 (85.7%) | 1 (14.3%) | ||
| IV | 12 (50.0%) | 12 (50.0%) | ||
| NA | 1 (100.0%) | 0 (0%) | ||
| Histology | Adenocarcinoma | 26 (53.1%) | 23 (46.9%) | 0.29 |
| Squamous carcinoma | 1 (100.0%) | 0 (0%) | ||
| Signet ring cell carcinoma | 0 (0%) | 2 (100.0%) | ||
| Others | 3 (75.0%) | 1 (25.0%) | ||
| EBER | Negative | 28 (59.6%) | 19 (40.4%) | 0.30 |
| Positive | 1 (25.0%) | 3 (75.0%) | ||
| NA | 1 (20.0%) | 4 (80.0%) | ||
| Duration of preoperative therapy | 1–2 months | 5 (55.6%) | 4 (44.4%) | 0.78 |
| 2–3 months | 13 (54.2%) | 11 (45.8%) | ||
| 3-4 months | 7 (63.6%) | 4 (36.4%) | ||
| Over 4 months | 5 (41.7%) | 7 (58.3%) | ||
Statistically significant P values are given in bold (P < 0.05); Liver metastasis, LN metastasis, and peritoneal metastasis are clinical staging before starting chemotherapy
dMMR deficiency of mis-match repair; Effective in TRG: got 0 or 1 in TRG; Effective in TRG: got 0 or 1 in TRG; MMR Mis-match repair, pCR pathological complete response, PD Progressive disease, pMMR proficiency of mismatch repair; Poor differentiation included the low differentiation and low-median differentiation; PR Partial response, RECIST Response evaluation criteria in solid tumors, SD Stable disease, TRG Tumor regression grade